Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Have novel drugs made stem cell transplantation obsolete?

David Maloney • 14 Jun 2017
ICML 2017
Non-Hodgkin Lymphoma

David Maloney, MD, PhD from the Fred Hutchinson Cancer Center, Seattle, WA reviews the spirited debate entitled, ‘Have new drugs made stem cell transplantation obsolete’, which took place during the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. The consensus from the debate was that, while the treatment landscape in lymphoma is moving towards more targeted therapies, stem cell transplantation is the only available ‘cure’ for high-risk patients and so it is not superseded by novel agents.

More from David Maloney

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022
4:36
Highlights from the immunotherapy in CLL session
David Maloney • 20 Sep 2021

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals